Rectiv Supply Disruption: A Provider-Focused Overview

Rectiv (Nitroglycerin 0.4% rectal ointment) remains the only FDA-approved topical treatment for moderate-to-severe pain associated with chronic anal fissures. However, ongoing supply disruptions continue to create significant barriers to patient access in 2026.

This article provides prescribers and clinical staff with an overview of the current shortage landscape, evidence-based prescribing alternatives, and practical strategies for supporting patients who cannot obtain Rectiv.

Current Supply Status

As of early 2026, Rectiv availability remains inconsistent across the United States. The medication is produced exclusively by Allergan (now a subsidiary of AbbVie), and no FDA-approved generic equivalent exists. These structural factors — single-source manufacturing and absence of generic competition — have created a chronic supply vulnerability that has persisted for several years.

Key factors contributing to the ongoing shortage include:

• Single-source production: Allergan/AbbVie is the sole manufacturer. Any production delay or capacity constraint directly impacts nationwide availability.
• No generic pathway: No ANDA for Nitroglycerin 0.4% rectal ointment has been approved by the FDA as of 2026.
• Low commercial volume: The relatively small patient population reduces manufacturer incentive for production scale-up and limits pharmacy willingness to maintain inventory.
• Distribution inefficiencies: Even when product is manufactured, distribution patterns may favor certain regions or pharmacy networks over others.

Clinical Impact on Patient Care

The practical consequences of the Rectiv shortage for your patients are significant:

• Patients may call multiple pharmacies without success, leading to treatment delays
• Untreated chronic anal fissures can progress, causing worsening pain, bleeding, and reduced quality of life
• Patients may discontinue treatment mid-course if they cannot refill their prescription
• Financial barriers compound access issues — when available, Rectiv carries a cash price of $500-$900+, and many insurance plans require prior authorization

Proactive communication with patients about potential access challenges and alternative treatment options is essential.

Evidence-Based Prescribing Alternatives

When Rectiv is unavailable, several alternatives have clinical support for the treatment of chronic anal fissures:

Compounded Nitroglycerin Ointment (0.2%-0.4%)

Compounding pharmacies can prepare Nitroglycerin ointment at the standard 0.4% concentration or at lower concentrations (e.g., 0.2%) based on clinical judgment. This represents the most pharmacologically equivalent alternative to Rectiv.

• Efficacy: Comparable to brand-name Rectiv when compounded at equivalent concentration
• Cost: Typically $30-$100 per preparation, significantly lower than brand pricing
• Availability: Generally more accessible through compounding pharmacy networks
• Limitations: Not FDA-approved; quality may vary across compounding facilities; patients should be counseled accordingly

Topical Diltiazem (2%)

Topical Diltiazem is a calcium channel blocker that reduces internal anal sphincter pressure through a different mechanism than Nitroglycerin. It is widely used as an alternative first-line topical agent for chronic anal fissures.

• Efficacy: Multiple studies demonstrate comparable fissure healing rates to Nitroglycerin. A Cochrane review found no statistically significant difference in healing outcomes.
• Tolerability: Significantly lower incidence of headache compared to Nitroglycerin (the primary side effect of Rectiv, reported in up to 64% of patients)
• Cost: Must be compounded; typically $30-$80
• Consideration: May be preferable for patients who discontinued Nitroglycerin due to headache

Topical Nifedipine (0.2%-0.5%)

Another calcium channel blocker option, compounded topically. Less commonly prescribed in U.S. practice but supported by international literature.

• Efficacy: Comparable to Diltiazem in available studies
• Tolerability: Similar side effect profile to Diltiazem
• Availability: Compounded preparation

Botulinum Toxin (Botox) Injection

For patients who have failed topical therapy or who cannot access topical agents, injection of botulinum toxin into the internal anal sphincter is an established second-line approach.

• Efficacy: Healing rates of 60-80% reported in literature
• Dosing: Typically 20-100 units injected into the internal anal sphincter; protocols vary by institution
• Considerations: Requires office or outpatient procedure; transient fecal incontinence reported in a minority of patients; may require repeat injection

Lateral Internal Sphincterotomy (LIS)

Surgical intervention remains the gold standard for refractory chronic anal fissures, with healing rates exceeding 90%. Reserved for patients who have failed medical management.

• Efficacy: Highest healing rates of any intervention (>90%)
• Risk: Small but non-negligible risk of long-term fecal incontinence (reported in 5-10% of patients, typically minor)
• Referral: Colorectal surgery referral appropriate for patients with persistent symptoms after adequate medical therapy trial

Practical Strategies for Managing Patient Access

Prescribing Workflow Adjustments

1. Proactively discuss alternatives at the time of initial Rectiv prescription. Inform patients that supply may be limited and outline backup options.
2. Include compounding pharmacy guidance in your discharge instructions or patient handouts. Provide specific pharmacy names if possible.
3. Consider prescribing Diltiazem 2% topical first if your clinical assessment supports it — this avoids the Rectiv supply issue entirely and may be better tolerated.
4. Use electronic prescribing to target pharmacies known to carry Rectiv or to compounding pharmacies directly.

Patient Resources to Recommend

• MedFinder for Providers — Real-time pharmacy availability search tool
• PCCA (Professional Compounding Centers of America) — Directory of compounding pharmacies
• AbbVie patient assistance programs — For patients with financial barriers
• NeedyMeds and RxAssist — Third-party financial assistance databases

Direct patients to our patient-facing resources as well:

• How to find Rectiv in stock near you
• Alternatives to Rectiv if you can't fill your prescription
• How to save money on Rectiv in 2026

Documentation and Prior Authorization Considerations

When Rectiv is available but requires prior authorization:

• Document the diagnosis of chronic anal fissure with ICD-10 code K60.1 (chronic anal fissure) or K60.2 (anal fissure, unspecified)
• Note failure of conservative measures (sitz baths, stool softeners, fiber supplementation) in the clinical record
• Include duration of symptoms and impact on quality of life
• Reference FDA-approved labeling for Rectiv to support medical necessity

When prescribing compounded alternatives, document clinical rationale including the unavailability of Rectiv.

Looking Ahead

The structural factors driving the Rectiv shortage — single-source manufacturing and absence of generic competition — are unlikely to resolve in the near term. Providers should prepare for continued intermittent supply disruptions and incorporate alternative treatment pathways into standard clinical workflows.

For additional provider-focused guidance, see: How to help your patients find Rectiv in stock: A provider's guide

Summary

Rectiv remains the only FDA-approved topical treatment for chronic anal fissure pain, but ongoing supply constraints require providers to be prepared with alternative prescribing strategies. Compounded Nitroglycerin and topical Diltiazem offer the most direct pharmacological alternatives, while botulinum toxin and surgery provide escalation pathways. Proactive patient communication and utilization of pharmacy search tools like MedFinder can help minimize treatment disruptions.